A Phase 1, Open-label, Single Dose Study to Investigate Pharmacokinetics, Safety and Tolerability of JNJ-63733657 in Healthy Chinese Participants
Latest Information Update: 06 Jan 2023
At a glance
- Drugs Posdinemab (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
Most Recent Events
- 03 Jan 2023 Status changed from recruiting to completed.
- 21 Jun 2022 Status changed from not yet recruiting to recruiting.
- 14 Jun 2022 New trial record